Biologics Approved In 2012
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA transferred review of most therapeutic biologics to the Center for Drug Evaluation & Research on Oct. 1, 2003. The Center for Biologics Evaluation & Research continues to review other biologics, including vaccines, cellular products, antitoxins and immunoglobulins.
You may also be interested in...
Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Brazil Authorizes Oxford/AZ and Sinovac Vaccines
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
UK Government Promise For 2021: No Halting The Advance Of Healthtech Innovation Adoption
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: